| Document |
Document Title |
|
WO/2013/020722 |
Compositions and methods comprising or using a combination of an amyloid beta mimotope and an adjuvant such as AS01B are provided. The compositions and methods provided are particularly useful for prevention or treatment of Alzheimer's d...
|
|
WO/2013/021353 |
An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the pro...
|
|
WO/2013/022717 |
The invention relates to compositions of purified filamentous bacteriophage, as well as methods that allow reproducible purification of high concentrations of filamentous bacteriophage.
|
|
WO/2013/020909 |
The present invention relates to surfen and derivatives and analogues thereofand their use in prevention and treatment of tauopathies, including Alzheimer's disease. Derivatives of surfen and novel medical uses and methods relating there...
|
|
WO/2013/021196 |
The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the ...
|
|
WO/2013/020966 |
The present disclosure relates to compounds to be used in a low dose in treatment of neurodegenerative diseases or disorders. It also relates to methods for treatment of a neurodegenerative diseases or disorders.
|
|
WO/2013/020368 |
This invention relates to extract, fractions and isolated compound of Rhodiola rosea, and uses thereof for treating neuropathological and neurodegenerative diseases. The extracts and compounds of the present invention inhibit the aggrega...
|
|
WO/2013/020724 |
The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as t...
|
|
WO/2013/018372 |
[Problem] To provide a novel amide derivative having greater safety and having superior phosphodiesterase 4 inhibition. [Solution] The novel amide derivative, which is represented by general formula (1), has strong PDE 4 inhibiting activ...
|
|
WO/2013/019938 |
Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2013/020136 |
The invention teaches a method and kit for treating traumatic brain injury, concussion and/or other conditions involving brain, head/neck and/or neurological injury. Specifically, the invention teaches the use of erythropoietin and stem ...
|
|
WO/2013/018883 |
The present invention identifies a cancer antigen protein that is specifically expressed at the surface of cancer cells, and provides an antibody having the protein as a target and an application of the antibody as a cancer treatment and...
|
|
WO/2013/017071 |
Disclosed are alicyclic[c] benzopyrone derivatives and uses thereof. The said alicyclic[c] benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity ...
|
|
WO/2013/017974 |
The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions...
|
|
WO/2013/018733 |
A 1,5-naphthyridine derivative represented by general formula [1] (wherein each of R1, R2, R3, R4 and R5 represents a hydrogen atom, an -L-Z group (wherein Z represents a non-aromatic heterocyclic group or the like, and L represents a si...
|
|
WO/2013/019711 |
The invention is directed to novel 17β-heteroaryl substituted steroids of Formula I, pharmaceutical compositions thereof, and their use as modulators of GABAA receptors.
|
|
WO/2013/018091 |
A composition of matter comprising non-cellular particles, which comprise a lysosomal enzyme and/or a small molecule which increases an amount and/or activity of a lysosomal enzyme.
|
|
WO/2013/017233 |
The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any peripherally or supraspinally mediated side effect in the subject. In particular, th...
|
|
WO/2013/018371 |
[Problem] To provide a biaryl ester derivative that is more safe and has superior phosphodiesterase 4 inibition. [Solution] The novel biaryl ester derivative, which is represented by general formula (1), and a pharmacologically acceptabl...
|
|
WO/2013/018008 |
A solution is disclosed having a pH 7.0 to 9.5, comprising alpha lipoic acid or its enantiomer, an inorganic compound and a solvent, said solvent being a mixture of water and a polyol. Said solution presents high stability of the alpha l...
|
|
WO/2013/018695 |
To provide a heterocyclic compound which has an RORγt inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group; Q represents a bonding hand or ...
|
|
WO/2013/017136 |
The present invention relates to a compound with the core structure of formula (I), or pharmaceutically acceptable salts or esters, solvates, or prodrugs thereof, for use in the treatment of cognitive impairment in a mammal. The compound...
|
|
WO/2013/017053 |
The present invention belongs to the field of biological products, and discloses a composite vaccine for preventing and treating Alzheimer's disease. The invention is formed by mixing code Aβ42 nucleic acid vaccine and protein gene engi...
|
|
WO/2013/018091 |
A composition of matter comprising non-cellular particles, which comprise a lysosomal enzyme and/or a small molecule which increases an amount and/or activity of a lysosomal enzyme.
|
|
WO/2013/017657 |
The present inventions relates to substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl- methanones of general formula (I) wherein R1, R2, R3, R4, R5 and R6 are as herein described or salts thereof, preferably pharmaceutically acceptable salts...
|
|
WO/2013/017068 |
Disclosed are a substituted benzopyran derivative and the use thereof. The substituted benzopyran derivative has the structure of formula (I). It has been found in experiments that the derivative can be used to prepare drugs for treating...
|
|
WO/2013/017619 |
Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related...
|
|
WO/2013/018374 |
[Problem] To provide a ketone derivative that has greater safety and that has superior phosphodiesterase 4 inhibition. [Solution] The novel ketone derivative, which is represented by general formula (1), has strong PDE 4 inhibitory activ...
|
|
WO/2013/014038 |
There are provided 3-oxo-2,3-dihydro-lH-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention...
|
|
WO/2013/016332 |
Disclosed are compositions for treating or preventing migraine headaches and related headaches.
|
|
WO/2013/014274 |
The present invention provides a novel compound of formula (I) useful for in vivo imaging of 5-HT1 A receptors in a subject. Also provided by the present invention is a precursor compound useful in the preparation of the compound of the ...
|
|
WO/2013/016727 |
Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, ...
|
|
WO/2013/016193 |
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof...
|
|
WO/2013/016073 |
The present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the al...
|
|
WO/2013/014629 |
The present invention relates to the use of compounds as angiogenesis inhibitors in the manufacture of a medicament for use in the treatment of disease states associated with angiogenesis, and anti-angiogenic pharmaceutical compositions ...
|
|
WO/2013/013815 |
The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the ...
|
|
WO/2013/013613 |
Disclosed is a use of G-CSF dimer in the preparation of medicament for treatment of neurodegenerative diseases. The G-CSF dimer molecules used in the present invention enable significant increase in quantity of nigra dopaminergic neurons...
|
|
WO/2013/013816 |
The invention relates to substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or ...
|
|
WO/2013/014921 |
A composition that exerts an effect that increases serotonin in the brain through ingestion is provided. This agent for increasing serotonin in the brain contains epicatechin, which is obtained by steaming and drying camellia leaves to o...
|
|
WO/2013/013817 |
The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further di...
|
|
WO/2013/016178 |
The present invention relates to novel N-(imidazolidin-2-ylidene)quino- line derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. Formula (I).
|
|
WO/2013/014185 |
The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activi...
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/013498 |
Chinese medicine beverage for nourishing the heart to calm the mind, wherein it is made of Tritucum aestivurn L., date, Liquorice Root and rose flower of Chinese medicine. The preparation method of such beverage is: weighing Chinese medi...
|
|
WO/2013/015152 |
Provided is an artificial gene expression inhibition method which can be designed more readily compared with conventional methods (an RNAi method, a ribozyme method, an antisense method), and in which the effect thereof can be confirmed ...
|
|
WO/2013/014204 |
The present invention relates to compounds of the formula I, wherein Ht, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cat...
|
|
WO/2013/013503 |
Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, ...
|
|
WO/2013/016193 |
The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof...
|
|
WO/2013/013338 |
The present invention discloses the use of substances targeting GC-C signaling pathway in the diagnosis and treatment for midbrain dopamine neurons diseases. One of the uses disclosed by the present invention is the method for constructi...
|
|
WO/2013/010453 |
Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compo...
|
